Charting the future of cancer health disparities research: A position statement from the American Association for Cancer Research, the American Cancer Society, the American Society of Clinical Oncology, and the National Cancer Institute

Cancer Research

Volumn 77, Issue 17, 2017, Pages 4548-4555

  Polite, Blase N ^a   Adams Campbell, Lucile L ^b   Brawley, Otis W ^c   Bickell, Nina ^d   Carethers, John M ^e   Flowers, Christopher R ^f   Foti, Margaret ^g   Gomez, Scarlett Lin ^h   Griggs, Jennifer J ^e   Lathan, Christopher S ⁱ   Li, Christopher I ^j   Lichtenfeld, J Leonard ^c   McCaskill Stevens, Worta ^k   Paskett, Electra D ^l  

^a UNIVERSITY OF CHICAGO   (United States)

^b GEORGETOWN UNIVERSITY   (United States)

^c AMERICAN CANCER SOCIETY   (United States)

^d MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^e UNIVERSITY OF MICHIGAN   (United States)

^f EMORY UNIVERSITY   (United States)

^g American Association for Cancer Research   (United States)

^h CANCER PREVENTION INSTITUTE OF CALIFORNIA   (United States)

ⁱ DANA FARBER CANCER INSTITUTE   (United States)

^j USA   (United States)

^k NATIONAL CANCER INSTITUTE   (United States)

^l OHIO STATE UNIVERSITY   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CANCER INCIDENCE; CANCER RESEARCH; CANCER RISK; CANCER SPECIFIC SURVIVAL; CLINICAL TRIAL (TOPIC); DATA COLLECTION METHOD; FUNDING; GENETIC PREDISPOSITION; HEALTH CARE ACCESS; HEALTH DISPARITY; HUMAN; MEDICALLY UNDERSERVED; MICROSATELLITE INSTABILITY; PATIENT PARTICIPATION; PERSONALIZED MEDICINE; PRIORITY JOURNAL; SOCIAL DETERMINANTS OF HEALTH; SOCIOECONOMICS; UNITED STATES; HEALTH CARE DISPARITY; NATIONAL HEALTH ORGANIZATION; NEOPLASM; NON PROFIT ORGANIZATION; ONCOLOGY; PRACTICE GUIDELINE; TRENDS;

AMERICAN CANCER SOCIETY; HEALTHCARE DISPARITIES; HUMANS; MEDICAL ONCOLOGY; NATIONAL CANCER INSTITUTE (U.S.); NEOPLASMS; PRACTICE GUIDELINES AS TOPIC; UNITED STATES;

EID: 85028877631     PISSN: 00085472     EISSN: 15387445     Source Type: Journal    
DOI: 10.1158/0008-5472.CAN-17-0623     Document Type: Article

References (53)

1. Fontaine SA, Henschke UK, Leffall LD Jr, Mason CH, Reinhold AW, Schneider R, et al. Comparison of the cancer deaths in the black and white USA population from 1949 to 1967. Med Ann Dist Columbia 1972;41:293–8.
2. Burbank F, Fraumeni JF Jr. US cancer mortality: nonwhite predominance. J Natl Cancer Inst 1972;49:649–59.
3. National Institutes of Health. Cancer health disparities. Available from: https://www.cancer.gov/about-nci/organization/crchd/cancer-health-disparities-fact-sheet#q1.
4. Braveman PA, Kumanyika S, Fielding J, LaVeist T, Borrell LN, Manderscheid R, et al. Health disparities and health equity: the issue is justice. Am J Public Health 2011;101:S149–S55.
5. Howlader N, Noone AM, Krapcho M, Miller D, Bishop K, Kosary CL, et al. SEER Cancer Statistics Review, 1975-2013 . Bethesda, MD: National Cancer Institute. Available from: http://seer.cancer.gov/csr/1975_2013/.
6. National Cancer Institute, Surveillance, Epidemiology, and End Results Program: Cancer of the Female Breast (Invasive). https://seer.cancer.gov/csr/1975_2014/results_merged/sect_04_breast.pdf.
7. Shariff-Marco S, Yang J, John EM, Kurian AW, Cheng I, Leung R, et al. Intersection of race/ethnicity and socioeconomic status in mortality after breast cancer. J Community Health 2015;40:1287–99.
8. Williams DR, Kontos EZ, Viswanath K, Haas JS, Lathan CS, MacConaill LE, et al. Integrating multiple social statuses in health disparities research: the case of lung cancer. Health Serv Res 2012;47:1255–77.
9. Warnecke RB, Oh A, Breen N, Gehlert S, Paskett E, Tucker KL, et al. Approaching health disparities from a population perspective: the National Institutes of Health centers for population health and health disparities. Am J Public Health 2008;98:1608–15.
10. Lynch SM, Rebbeck TR. Bridging the gap between biologic, individual, and macroenvironmental factors in cancer: a multilevel approach. Cancer Epidemiol Biomarkers Prev 2013;22:485–95.
11. Gomez SL, Shariff-Marco S, DeRouen M, Keegan TH, Yen IH, Mujahid M, et al. The impact of neighborhood social and built environment factors across the cancer continuum: current research, methodological considerations, and future directions. Cancer 2015;121:2314–30.
12. Institute of Medicine. The health of lesbian, gay, bisexual, and transgender people: building a foundation for better understanding. Washington, DC: The National Academies Press; 2001.
13. Lam TK, Spitz M, Schully SD, Khoury MJ. "Drivers" of translational cancer epidemiology in the 21st century: needs and opportunities. Cancer Epidemiol Biomarkers Prev 2013;22:181–8.
14. Palmer JR, Ambrosone CB, Olshan AF. A collaborative study of the etiology of breast cancer subtypes in African American women: the AMBER consortium. Cancer Causes Control 2014;25:309–19.
15. Bandera EV, Chandran U, Hong CC, Troester MA, Bethea TN, Adams-Campbell LL, et al. Obesity, body fat distribution, and risk of breast cancer subtypes in African American women participating in the AMBER Consortium. Breast Cancer Res Treat 2015;150:655–66.
16. Bethea TN, Rosenberg L, Hong CC, Troester MA, Lunetta KL, Bandera EV, et al. A case-control analysis of oral contraceptive use and breast cancer subtypes in the African American breast cancer epidemiology and risk consortium. Breast Cancer Res 2015;17:22.
17. Haddad SA, Lunetta KL, Ruiz-Narvaez EA, Bensen JT, Hong CC, Sucheston-Campbell LE, et al. Hormone-related pathways and risk of breast cancer subtypes in African American women. Breast Cancer Res Treat 2015; 154:145–4.
18. Han Y, Hazelett DJ, Wiklund F, Schumacher FR, Stram DO, Berndt SI, et al. Integration of multiethnic fine-mapping and genomic annotation to prioritize candidate functional SNPs at prostate cancer susceptibility regions. Hum Mol Genet 2015;24:5603–18.
19. Berndt SI, Wang Z, Yeager M, Alavanja MC, Albanes D, Amundadottir L, et al. Two susceptibility loci identified for prostate cancer aggressiveness. Nat Commun 2015;6:6889.
20. O'Keefe SJ, Li JV, Lahti L, Ou J, Carbonero F, Mohammed K, et al. Fat, fibre, and cancer risk in African Americans and rural Africans. Nat Commun 2015;6:6342.
21. Grubbs SS, Polite BN, Carney J Jr, Bowser W, Rogers J, Katurakes N, et al. Eliminating racial disparities in colorectal cancer in the real world: it took a village. J Clin Oncol 2013;31:1928–30.
22. Kupfer SS, Carr RM, Carethers JM. Reducing colorectal cancer risk among African Americans. Gastroenterology 2015;149:1302–4.
23. Carethers JM. Screening for colorectal cancer in African Americans: determinants and rationale for an earlier age to commence screening. Dig Dis Sci 2015;60:711–21.
24. Hunt BR, Whitman S, Hurlbert MS. Increasing black-white disparities in breast cancer mortality in the 50 largest cities in the United States. Cancer Epidemiol 2014;38:118–23.
25. Bickell NA, Shastri K, Fei K, Oluwole S, Godfrey H, Hiotis K, et al. A tracking and feedback registry to reduce racial disparities in breast cancer care. J Natl Cancer Inst 2008;100:1717–23.
26. Rhoads KF, Patel MI, Ma Y, Schmidt LA. How do integrated health care systems address racial and ethnic disparities in colon cancer? J Clin Oncol 2015;33:54–860.
27. National Academies of Sciences, Engineering, and Medicine. Systems practices for the care of socially at-risk populations. Washington, DC: The National Academies Press; 2016.
28. Carethers JM, Murali B, Yang B, Doctolero RT, Tajima A, Basa R, et al. Influence of race on microsatellite instability and CD8þ T cell infiltration in colon cancer. PLoS One 2014;9:e100461.
29. Guda K, Veigl ML, Varadan V, Nosrati A, Ravi L, Lutterbaugh J, et al. Novel recurrently mutated genes in African American colon cancers. Proc Natl Acad Sci USA 2015;112:1149–54.
30. American College of Surgeons. Rapid quality reporting system (RQRS). Available from: https://www.facs.org/quality-programs/cancer/ncdb/qualitytools/rqrs.
31. Maitland ML, DiRienzo A, Ratain MJ. Interpreting disparate responses to cancer therapy: the role of human population genetics. J Clin Oncol 2006;24:2151–7.
32. Collins FS, Varmus H. A new initiative on precision medicine. N Engl J Med 2015;372:793–5.
33. Collins FS, Hamburg MA. First FDA authorization for next-generation sequencer. N Engl J Med 2013;369:2369–71.
34. Feero WG, Guttmacher AE, Collins FS. Genomic medicine: an updated primer. N Engl J Med 2010;362:2001–11.
35. Guttmacher AE, Collins FS. Welcome to the genomic era. N Engl J Med 2003;349:996–8.
36. Hamburg MA, Collins FS. The path to personalized medicine. N Engl J Med 2010;363:301–304.
37. Hudson KL, Holohan MK, Collins FS. Keeping pace with the times: the genetic information nondiscrimination act of 2008. N Engl J Med 2008;358:2661–3.
38. Collins FS. Shattuck lecture. Medical and societal consequences of the human genome project. N Engl J Med 1999;341:28–37.
39. Barkin S, Schlundt D, Smith P. Community-engaged research perspectives: then and now. Acad Pediatr 2013;13:93–7.
40. Institute of Medicine. Crossing the quality chasm: a new health system for the 21st century. Washington, DC: National Academies Press; 2001.
41. Institute of Medicine. Unequal treatment. Washington, DC: The National Academies Press; 2003.
42. Tapp H, White L, Steuerwald M, Dulin M. Use of community-based participatory research in primary care to improve health care outcomes and disparities in care. J Comp Eff Res 2013;2:405–19.
43. Stange KC, Breslau ES, Dietrich AJ, Glasgow RE. State-of-the-art and future directions in multilevel interventions across the cancer control continuum. J Natl Cancer Inst Monogr 2012;2012:20–31.
44. Colditz GA, Wolin KY, Gehlert S. Applying what we know to accelerate cancer prevention. Sci Transl Med 2012;4:127rv4.
45. Institute of Medicine. The unequal burden of cancer: an assessment of NIH research and programs for ethnic minorities and the medically underserved. Washington, DC: The National Academies Press; 1999.
46. National Science Foundation. Division of science resources statistics: women, minorities, and persons with disabilities in science and engineering: 2011. Special Report NSF 11-309. Arlington, VA: National Science Foundation; 2011. Available from: http://www.nsf.gov/statistics/wmpd/.
47. Institute of Medicine. A National Cancer Clinical trials system for the 21st Century: reinvigorating the NCI Cooperative Group Program. Washington, DC: The National Academies Press; 2010.
48. Adams-Campbell LL, Ahaghotu C, Gaskins M, Dawkins FW, Smoot D, Polk OD, et al. Enrollment of African Americans onto clinical treatment trials: study design barriers. J Clin Oncol 2004;22:730–4.
49. Ford JG, Howerton MW, Lai GY, Gary TL, Bolen S, Gibbons MC, et al. Barriers to recruiting underrepresented populations to cancer clinical trials: a systematic review. Cancer 2008;112:228–42.
50. Arnold KB, Hermos JA, Anderson KB, Minasian L, Tangen CM, Probstfield JF, et al. Retention of black and white participants in the selenium and vitamin E cancer prevention trial (SWOG-coordinated intergroup study S0000). Cancer Epidemiol Biomarkers Prev 2014;23:2895–905.
51. Greiner KA, Friedman DB, Adams SA, Gwede CK, Cupertino P, Engelman KK, et al. Effective recruitment strategies and community-based participatory research: community networks program centers' recruitment in cancer prevention studies. Cancer Epidemiol Biomarkers Prev 2014;23:416–23.
52. Fouad MN, Johnson RE, Nagy MC, Person SD, Partridge EE. Adherence and retention in clinical trials: a community-based approach. Cancer 2014;120:1106–12.
53. Cancer and Aging Research Group. Available from: http://www.mycarg.org.